On behalf of Genentech, Inc., I respectfully request the NCCN Cervical Cancer Guideline Panel to review the enclosed recent key publication for:

- **Avastin® (bevacizumab):** Chemotherapy-naïve recurrent cervical cancer


**Specific Changes:**
There are no specific changes being requested. We are providing the full manuscript of previously submitted data on Avastin in chemotherapy-naïve recurrent cervical cancer for your review and consideration.

**FDA Clearance:** Avastin is not FDA approved for cervical cancer.

Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.

**Rationale:**
- Efficacy and safety results of the phase III trial evaluating Avastin in chemotherapy-naïve recurrent cervical cancer were previously submitted. The recently published full manuscript for this study is being submitted for your review.

Respectfully submitted,

Supplemental References


